Linked Life Data

2279989

Source:http://linkedlifedata.com/resource/pubmed/id/2279989

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1991-3-8
pubmed:abstractText
Cell-to-cell fusion plays an important role in the pathogenesis of human immunodeficiency virus type 1 (HIV-1) infections. An assay to measure the antifusion activity of serum has been developed by using the fusion event that occurs between H9 cells chronically infected with HIV-1 (H9IIIB) and fusion-susceptible MT-2 cells. The endpoint is determined by measuring neutral red uptake in cells after syncytium formation is allowed to occur in the presence of various serum dilutions. The assessment of antifusion activity in serum by neutral red uptake has been shown to correlate with syncytium reduction as determined by direct counting. The optimal number and ratio of cells in the suspension for efficiency and speed of the assay have been determined. With this assay it was shown that 50% of 36 serum specimens capable of neutralizing cell-free virions failed to inhibit syncytium formation. The assay can thus measure a distinct activity in HIV-1-immune human sera which is a subset of neutralization activity. Because of the potential role of this activity in the rate of disease progression and protective immune responses, the antifusion assay will be an important tool for the investigation of disease pathogenesis and for acquired immunodeficiency syndrome vaccine development. The assay can also be applied to the investigation of the pathogenesis of the fusion event at the cellular level. The ability to use absorbance measurements rather than syncytium counts as the endpoint facilitates direct computer-assisted data analysis, which expedites the performance of the assay.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-2543075, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-2821680, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-2991110, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-2992081, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-3010463, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-3016552, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-3422647, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-3629244, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-3646751, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-6200935, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-6224029, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-6275274, http://linkedlifedata.com/resource/pubmed/commentcorrection/2279989-6766174
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0095-1137
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2608-11
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Antifusion activity in sera from persons infected with human immunodeficiency virus type 1.
pubmed:affiliation
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.